secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001558370-24-009170
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path interim Phase 2 data: 75% CR/CRh/CRi in newly diagnosed AML with prexigebersen combo
--------------------------------------------------------------------------------

- Cohort 1 (newly diagnosed): 15/20 evaluable patients achieved CR/CRh/CRi; median age 75, adverse-risk or secondary AML.
- Cohort 2 (relapsed/refractory): 55% of evaluable patients (12/23) achieved CR/CRh/CRi with same triple combination.
- Most common severe adverse events: febrile neutropenia (26%) and sepsis (5%); safety consistent with backbone therapy.
- Company to continue enrollment up to 98 evaluable for Cohort 1 and 54 for Cohort 2.
- Results presented at EHA Congress 2024; CEO highlights potential as additional AML treatment option.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024009170/0001558370-24-009170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024009170/bpth-20240614x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer